Everything below concerns Immune modulation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-28. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Surrounding skin: Appearance of the surrounding skin can provide clues to underlying disease processes, such as redness/erythema due to cellulitis, maceration due to uncontrolled wound exudate, or eczematous changes due to a chronic irritation (e.g. allergic reaction to wound dressing). Infection: Classic signs of infection are redness, warmth, swelling, odor, and pain out of proportion to wound appearance. Pain: Pain can be nociceptive, neuropathic, or inflammatory, each of which can provide clues to the cause of a wound. Proper pain control is an important consideration in wound management, particularly in burn care where analgesia is often necessary prior to dressing changes. A thorough wound evaluation, particularly evaluation of wound depth and removal of necrotic tissue, should be performed only by a licensed healthcare professional in order to avoid damage to nearby structures, infection, or worsening pain.
=== Turnover and cell renewal === Cell division occurs predominantly in the basal layer, with cells migrating coronally and superficially. The turnover rate is slower than the junctional epithelium but faster than fully keratinized gingival epithelium.
=== Bibliography === Amis, Martin (2000). Experience. Vintage. ISBN 978-0-099-28582-3. Blundell, Nigel (1996). Encyclopaedia of Serial Killers. Promotional Reprint Company Ltd. ISBN 978-1-856-48328-5. Burn, Gordon (1998). Happy Like Murderers. Faber and Faber (London). ISBN 978-0-571-19546-6. Carter Woodrow, Jane (2011). Rose West: The Making of a Monster. Hodder & Stoughton. ISBN 9781848946866. Cawthorne, Nigel (2007). Serial Killers and Mass Murderers: Profiles of the World's Most Barbaric Criminals. Ulysses Press. ISBN 978-1-569-75578-5. Cresswell, Kim (2016). Garden of Bones - The Story of Fred and Rosemary West. KC Publishing. ISBN 9780995057807. Roberts, Caroline (2005). The Lost Girl: How I Triumphed Over Life at the Mercy of Fred and Rose West. Metro Books (London). ISBN 978-1-84358-088-1. Sounes, Howard (1995). Fred and Rose: The Full Story of Fred and Rose West and the Gloucester House of Horrors. Warner Books (London). ISBN 978-0-7515-1322-6. Wansell, Geoffrey (1996). An Evil Love: The Life of Frederick West. Hodder Headline (London). ISBN 978-0-7472-1760-2. West, Anne Marie (1995). Out of the Shadows: Fred West's Daughter Tells Her Harrowing Story of Survival. Simon & Schuster. ISBN 978-0-671-71968-5. Wilson, Colin (1998). The Corpse Garden. True Crime Library (London). ISBN 978-1-874358-24-4. "Fred & Rosemary West". Murder in Mind. No. 1. 1996. ISSN 1364-5803.
=== Civilian === Although the majority of the world's submarines are military, there are some civilian submarines, which are used for tourism, exploration, oil and gas platform inspections, and pipeline surveys. Some are also used in illegal activities. The Submarine Voyage ride opened at Disneyland in 1959, but although it ran under water, it was not a true submarine, as it ran on tracks and was open to the atmosphere. The first tourist submarine was Auguste Piccard, which went into service in 1964 at Expo64. By 1997, there were 45 tourist submarines operating around the world. Submarines with a crush depth in the range of 400–500 feet (120–150 m) are operated in several areas worldwide, typically with bottom depths around 100 to 120 feet (30 to 37 m), with a carrying capacity of 50 to 100 passengers. In a typical operation a surface vessel carries passengers to an offshore operating area and loads them into the submarine. The submarine then visits underwater points of interest such as natural or artificial reef structures. To surface safely without danger of collision the location of the submarine is marked with an air release and movement to the surface is coordinated by an observer in a support craft. A recent development is the deployment of so-called narco-submarines by South American drug smugglers to evade law enforcement detection. Although they occasionally deploy true submarines, most are self-propelled semi-submersibles, where a portion of the craft remains above water at all times.
== Overview == A true endoskeleton is derived from mesodermal tissue. In three phyla of animals, Chordata (chordates), Echinodermata (echinoderms) and Porifera (sponges), endoskeletons of various complexity are found. An endoskeleton may function purely for structural support (as in the case of Porifera), but often also serves as an attachment site for muscles and a mechanism for transmitting muscular forces as in chordates and echinoderms, which provides a means of locomotion. Compared to the exoskeleton structure in many invertebrates (particularly panarthropods), the endoskeleton has several advantages:
Sources: en.wikipedia.org
The structure of the AG glycans consists of a backbone of β-1,3 linked galactose (Gal), with sidechains of β-1,6 linked Gal and have terminal residues of arabinose (Ara), rhamnose (Rha), Gal, fucose (Fuc), and glucuronic acid (GlcA). These AG glycan moieties are assembled by glycosyltransferases (GTs). O-glycosylation of AGPs is initiated by the action of Hyp-O-galactosyltransferases (Hyp-O-GalTs) that add the first Gal onto the protein. The complex glycan structures are then elaborated by a suite of glycosyltransferases, the majority of which are bio-chemically uncharacterized. The GT31 family is one of the families involved in AGP glycan backbone biosynthesis. Numerous members of the GT31 family have been identified with Hyp-O-GALT activity and the core β-(1,3)-galactan backbone is also likely to be synthesized by the GT31 family. Members of the GT14 family are implicated in adding β-(1,6)- and β-(1,3)-galactans to AGPs. In Arabidopsis, terminal sugars such as fucose are proposed to be added by AtFUT4 (a fucosyl transferase) and AtFUT6 in the GT37 family and the terminal GlcA incorporation can be catalysed by the GT14 family. A number of GTs remain to be identified, for example those responsible for terminal Rha.
As a result, it is often combined with these drugs to reduce their side-effect profile and to produce a stronger antidepressant effect. Mirtazapine does not have pro-serotonergic activity and thus does not cause serotonin syndrome. This is in accordance with the fact that it is not a serotonin reuptake inhibitor or monoamine oxidase inhibitor, nor a serotonin receptor agonist. There are no reports of serotonin syndrome in association with mirtazapine alone, and mirtazapine has not been found to cause serotonin syndrome in overdose. However, there are a handful of case reports of serotonin syndrome occurring with mirtazapine in combination with serotonergic drugs like selective serotonin reuptake inhibitors, although such reports are very rare, and do not necessarily implicate mirtazapine as causative.
== Side effects == The side effects of nicergoline are usually limited to nausea, hot flushes, mild gastric upset, hypotension and dizziness. At high drug dosages, bradycardia, increased appetite, agitation, diarrhea and perspiration were reported. Most of the available literature suggests that the side effects of nicergoline are mild and transient.
== Taxonomy == Xestospongia testudinaria var. fistulophora Wilson, 1925 Like all sponges, Xestospongia testudinaria exhibit species-specific microbiome. Recent studies on Xestospongia testudinaria microbiome revealed that morphologically similar specimens hosted significantly different microbiomes, hinting towards the occurrence of cryptic speciation.
Sources: en.wikipedia.org
=== 250Cm === Curium-250 is the isotope with the lowest atomic number that primarily decays by spontaneous fission, a process that releases many times more energy than alpha decay. Compared to plutonium-238, curium-250 has about a quarter of the power density, but 95 times the half-life (~8300 years vs. ~87 years). As it is a neutron emitter (weaker than californium-252 but not negligible) some applications require a further shielding against neutron radiation. As lead, which is an excellent shielding material against gamma rays and beta ray induced Bremsstrahlung, is not a good neutron shield (instead reflecting most of them), a different shielding material would have to be added in applications where neutrons are a concern.
It also raised tariffs on imports of Chinese steel, aluminum, and medical materials. In April 2024, Biden signed the Protecting Americans from Foreign Adversary Controlled Applications Act, which would ban social networking services if they are determined by the president and relevant provisions to be a "foreign adversary controlled application". The act explicitly applies to ByteDance Ltd. and its subsidiaries, which are based in China. It ceases to be applicable if the application is divested and no longer considered to be controlled by a foreign adversary of the United States. Biden had signed the No TikTok on Government Devices Act in December 2022, prohibiting the use of TikTok on devices owned by the federal government.
==== Phenylpiperazines/quinolinones/benzoxazinones ==== Aripiprazole (Abilify) - Partial agonist at the D2 receptor. Considered the prototypical third-generation antipsychotic. Aripiprazole lauroxil (Abilify Maintena) – Long-acting version of aripiprazole for injection. Brexpiprazole (Rexulti) – Partial agonist of the D2 receptor. Successor of aripiprazole. Brilaroxazine – A D2/3/4 and 5-HT1A partial agonist and 5-HT2A/2B/7 antagonist Cariprazine (Vraylar, Reagila) – A D3-preferring D2/3 partial agonist.
Alanine (symbol Ala or A), or α-alanine, is an α-amino acid that is used in the biosynthesis of proteins. It contains an amine group and a carboxylic acid group, both attached to the central carbon atom which also carries a methyl group side chain. Consequently it is classified as a non-polar, aliphatic α-amino acid. Under biological conditions, alanine exists in its zwitterionic form with its amine group protonated (as −NH+3) and its carboxyl group deprotonated (as −CO−2). Alanine is encoded by all codons starting with GC (GCU, GCC, GCA, and GCG). The L-isomer of alanine (left-handed) is the one that is incorporated into proteins. L-alanine is second only to L-leucine in rate of occurrence, accounting for 7.8% of the primary structure in a sample of 1,150 proteins. The right-handed form, D-alanine, occurs in peptides in some bacterial cell walls (in peptidoglycan) and in some peptide antibiotics, and occurs in the tissues of many crustaceans and molluscs as an osmolyte. Alanine is not an essential amino acid in humans because it can be synthesized metabolically and does not need to be present in the diet. However hypoalaninemia (alanine deficiency) is possible under certain conditions such as ketotic hypoglycemia.
== Plant protein research == The first biochemist to enter the field was Karl Heinrich Ritthausen, a student of Justus von Liebig. Thomas Burr Osborne continued what Ritthausen started and published The Vegetable Proteins in 1909. Thus Yale University was the early center of protein nutrition, where William Cumming Rose was a student. Osborne also worked to determine the essentials, and later led the Biochemistry Department at the University of Chicago. When Ritthausen died in 1912, Osborne praised his efforts in biochemistry:
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.